$216.00
+4.00 (+1.89%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RVMD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
17 interventional · 1 expanded access · 2 with posted results
Held by 18 tracked-famous managers (Holocene Advisors, LP, AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, Duquesne Family Office LLC, +13 more) · FINRA short interest 6.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 21 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338Number of patients with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only) | Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC | 370 | May 2029 | ≤ 1,016 d | 2026-08-03 |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)NCT07252232Disease-Free Survival (DFS) per InvestigatorRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: daraxonrasib | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma | 500 | 2029-05-10 | in 995 d | 2026-07-31 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsNCT06128551Number of patients with adverse events (AEs) in Phase 1bNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Elironrasib, Daraxonrasib | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | 534 | Dec 2028 | ≤ 865 d | 2026-08-03 |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )NCT07621718Progression free survival (PFS)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | 670 | 2028-12-30 | in 864 d | 2026-08-03 |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07491445Progression free survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: daraxonrasib, gemcitabine, nab-paclitaxel | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | 900 | Jun 2028 | ≤ 681 d | 2026-08-18 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537Number of patients with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: RMC-5127, daraxonrasib, cetuximab | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors | 574 | Apr 2028 | ≤ 620 d | 2026-07-10 |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: daraxonrasib, docetaxel | NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer) | 590 | 2027-12-01 | in 469 d | 2026-08-06 |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221Adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805 | Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC | 616 | Jun 2027 | ≤ 315 d | 2026-06-30 |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT05379985Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signsOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | 754 | 2027-05-31 | in 285 d | 2026-05-15 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsNCT06445062Adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 1,130 | 2027-05-15 | in 269 d | 2026-07-29 |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsNCT05462717Adverse eventsOpen-label · Treatment | Phase 1 | Active, not recruiting | Drug: RMC-6291 | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor | 222 | 2027-03-31 | in 224 d | 2026-05-15 |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541Adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: RMC-9805, RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | 604 | 2026-12-31 | in 134 d | 2026-06-03 |
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320Progression free survival (PFS) in the RAS G12-mutant populationRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | 500 | Jun 2026 | — | 2026-06-02 |
| Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesNCT05054725results2026-01-06Objective Response Rate (ORR) as Assessed Per RECIST v1.1Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: RMC-4630, Sotorasib | Non-Small Cell Lung Cancer | 47 | 2024-07-03actual | — | 2026-01-06 |
| Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsNCT04774952Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Completed | Drug: RMC-5552 | Solid Tumors | 58 | 2024-05-06actual | — | 2025-04-15 |
| Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsNCT03634982Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Unknown status | Drug: RMC-4630 | Solid Tumors | 133 | 2023-03-31 | — | 2022-09-01 |
| Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCNCT03989115results2023-06-26Number of Participants With Adverse Events (AEs).Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: RMC-4630, Cobimetinib, Drug: Osimertinib | Solid Tumor | 113 | 2022-02-08actual | — | 2023-06-26 |
| Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaNCT07573215expanded access | — | Available | Drug: daraxonrasib | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | — | — | — | 2026-08-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19